In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Peter P. Pfreundschuh net worth and biography

Peter Pfreundschuh Biography and Net Worth

CFO of Frequency Therapeutics

Peter is Frequency Therapeutics’ Chief Financial Officer. He joined Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as Chief Financial Officer, Chief Compliance Officer and Corporate Secretary. He brings to Frequency more than 20 years of finance, business development, commercial and public company leadership experience in the life sciences and medical device industries. Prior to joining UroGen, Peter was the CFO of Sucampo Pharmaceuticals Inc., where he co-led the sale of the company to Mallinckrodt, was EVP and CFO of Immunomedics Inc., and was CFO of the heart pump maker, CircuLite Inc. Pfreundschuh also has held senior roles across finance, commercial operations and business development within the pharmaceutical industry at AstraZeneca Pharmaceuticals and Johnson & Johnson. He started his career as an auditor at Ernst & Young, LLP.

Peter is a certified public accountant and holds a Master of Business Administration in finance from Rider University. He has completed master’s coursework in strategic marketing from Northwestern University’s Kellogg School of Management and received his Bachelor of Science in accounting from Rutgers University. Mr. Pfreundschuh is currently on the Boards of Speratus Therapeutics Inc., and GitBasic.

What is Peter P. Pfreundschuh's net worth?: The estimated net worth of Peter P. Pfreundschuh is at least $44,770.13 as of October 3rd, 2023. Mr. Pfreundschuh owns 149,433 shares of Frequency Therapeutics stock worth more than $44,770 as of November 16th. This net worth evaluation does not reflect any other assets that Mr. Pfreundschuh may own. Learn More about Peter P. Pfreundschuh's net worth.
How do I contact Peter P. Pfreundschuh?: The corporate mailing address for Mr. Pfreundschuh and other Frequency Therapeutics executives is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. Frequency Therapeutics can also be reached via phone at 781-315-4600 and via email at [email protected]. Learn More on Peter P. Pfreundschuh's contact information.
Has Peter P. Pfreundschuh been buying or selling shares of Frequency Therapeutics?: Peter P. Pfreundschuh has not been actively trading shares of Frequency Therapeutics during the last ninety days. Most recently, Peter P. Pfreundschuh sold 1,542 shares of the business's stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $3.53, for a transaction totalling $5,443.26. Learn More on Peter P. Pfreundschuh's trading history.
Who are Frequency Therapeutics' active insiders?: Frequency Therapeutics' insider roster includes Carl LeBel (Insider), Christopher Loose (Insider), Quentin McCubbin (Insider), and Peter Pfreundschuh (CFO). Learn More on Frequency Therapeutics' active insiders.

Peter P. Pfreundschuh Insider Trading History at Frequency Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/22/2022	Sell	1,542	$3.53	$5,443.26
2/18/2022	Sell	1,404	$3.88	$5,447.52
2/15/2022	Sell	1,347	$4.33	$5,832.51

Peter P. Pfreundschuh Buying and Selling Activity at Frequency Therapeutics

Frequency Therapeutics Company Overview

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $0.30

$0.28

$0.32

50 Day Range

MA: $0.58

$0.22

$14.98

2 Week Range

Now: $0.30

$0.18

$16.00

Volume

309,164 shs

Average Volume

822,537 shs

Market Capitalization

$10.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad